Skip to content
value.today

Chase Pharmaceuticals Corp

Total raised
$23 M
4 rounds on record
Latest round
$12 M
Mar 2016
First round on record
Nov 2010
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Chase Pharmaceuticals Corp
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2016$12 MNo. 4$10 to $50 million

Chase Pharmaceuticals Corp: Raise no. 4, Mar 2016

Investors in this round

14 investors had bought by the notice of Mar 28, 2016: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kathleen N. Clarence-Smith · Executive Officer
  • Thomas N. Chase · Executive Officer, Director
  • John M. Reher · Director
  • Karoly N. Nikolich · Director
  • Nayan Greg Parekh · Director
  • Raphael M. Wisniewski · Director
  • Stephen N. Cunningham · Director
  • Vikram M. Sudarsan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Douglas Ingram, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 28, 2016. Read the notice at the SEC.

equity, optionsSEC
Aug 2015$4 MNo. 3$2 to $10 million

Chase Pharmaceuticals Corp: Raise no. 3, Aug 2015

Investors in this round

13 investors had bought by the notice of Feb 17, 2016: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John M. Reher · Director, Executive Officer
  • Kathleen N. Clarence-Smith · Executive Officer
  • Thomas N. Chase · Executive Officer, Director
  • Douglas Ingram · Director
  • Karoly N. Nikolich · Director
  • Nayan Greg Parekh · Director
  • Raphael M. Wisniewski · Director
  • Stephen N. Cunningham · Director
  • Vikram M. Sudarsan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “This filing covers the sale and issuance of Series B-1A Preferred Stock, the Common Stock issuable upon conversion thereof and the sale and issuance of Warrants exercisable for Series B-1A Preferred Stock and the stock issuable upon conversion thereof.”

Signed by Douglas Ingram, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Feb 17, 2016. Read the notice at the SEC.

equity, optionsSEC
May 2014$6 MNo. 2$2 to $10 million

Chase Pharmaceuticals Corp: Raise no. 2, May 2014

Investors in this round

6 investors had bought by the notice of May 30, 2014: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $9 M offered; $2 M still to sell
Smallest investment taken
$1
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • John M. Siebert · Executive Officer, Director
  • Greg N. Parekh · Director
  • John M. Reher · Director
  • Karoly N. Nikolich · Director
  • Raphael N. Wisniewski · Director
  • Thomas N. Chase · Director
  • Vikram N. Sudarsan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “This filing covers the sale and issuance of Series B-1 Preferred Stock, the Common Stock issuable upon conversion thereof, and the sale and issuance of Series B-1 Preferred Stock Warrants and the Common Stock issuable upon conversion thereof.”

Signed by John M. Siebert, President and Chief Executive Officer. Source: SEC Form D, newest notice filed May 30, 2014. Read the notice at the SEC.

equity, optionsSEC
Nov 2010$1 MNo. 1Under $2 million

Chase Pharmaceuticals Corp: Raise no. 1, Nov 2010

Investors in this round

1 investor had bought by the notice of Jan 5, 2011: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kathleen P. Clarence-Smith · Executive Officer, Director
  • Richard P. Dulik · Executive Officer
  • Thomas N. Chase · Executive Officer, Director
  • John M Reher · Director
  • Karoly M Nikolich · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas N. Chase, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 5, 2011. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Chase Pharmaceuticals Corp chose not to state its revenue in its newest notice of a funding round (Mar 2016).

    SEC Form D · Mar 2016

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Mar 2016

That is all the official record says: Chase Pharmaceuticals Corp has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Chase Pharmaceuticals Corp is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 14 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Chase Pharmaceuticals Corp
NameRoleNamed in
Kathleen N. Clarence-SmithExecutive officerMar 2016
Thomas N. ChaseExecutive officerMar 2016
John M. ReherExecutive officerFeb 2016
John M. SiebertExecutive officerAug 2015
Kathleen P. Clarence-SmithExecutive officerJan 2011
Richard P. DulikExecutive officerJan 2011
John M. ReherDirectorMar 2016
Karoly N. NikolichDirectorMar 2016
Nayan Greg ParekhDirectorMar 2016
Raphael M. WisniewskiDirectorMar 2016
Stephen N. CunninghamDirectorMar 2016
Thomas N. ChaseDirectorMar 2016
Vikram M. SudarsanDirectorMar 2016
Douglas IngramDirectorFeb 2016
N. Greg ParekhDirectorAug 2015
Greg N. ParekhDirectorMay 2014
John M. SiebertDirectorMay 2014
Raphael N. WisniewskiDirectorMay 2014
Vikram N. SudarsanDirectorMay 2014
John M ReherDirectorJan 2011
Karoly M NikolichDirectorJan 2011
Kathleen P. Clarence-SmithDirectorJan 2011